title,link,date
"Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 1d - Dr. Reddy's FY25 revenues $3.8B, EBITDA $1B+, double-digit growth, biosimilars progress, NRT acquisition integration.",https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cb1a643-d837-43d0-a5e2-8c283e1664e6.pdf,"1d - Dr. Reddy's FY25 revenues $3.8B, EBITDA $1B+, double-digit growth, biosimilars progress, NRT acquisition integration."
"Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d - Dr. Reddy's management to attend Ambit Capital investor meetings in Boston, New York, Chicago from May 20-23, 2025.",https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89061e8c-ec94-4c26-8abc-4882127b09d9.pdf,"2d - Dr. Reddy's management to attend Ambit Capital investor meetings in Boston, New York, Chicago from May 20-23, 2025."
Announcement under Regulation 30 (LODR)-Newspaper Publication 10 May,https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bbc1a1c3-15bd-413e-9cf8-14b5049e4aa1.pdf,10 May
"Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 10 May - Audio recording of Q4 FY2025 earnings call released on May 9, 2025.",https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3408ff2-52ad-4d42-983f-5bafd3d3d0c8.pdf,"10 May - Audio recording of Q4 FY2025 earnings call released on May 9, 2025."
"Disclosure Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Incorporation Of Step Down Wholly-Owned Subsidiary 9 May - Dr. Reddy's Q4 FY25 reports record ₹32,554 Cr revenue, 17% growth, new partnerships, and USFDA biosimilar filing acceptance.",https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1eec76c0-0b5e-4d02-81f9-00426300f249.pdf,"9 May - Dr. Reddy's Q4 FY25 reports record ₹32,554 Cr revenue, 17% growth, new partnerships, and USFDA biosimilar filing acceptance."
